← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 21.3% to $403.1M, while Net income increased 56.2% to ($22.7M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $403.1MWatch
- Profitability — Net income ($22.7M)Watch
- Cash generation — Free cash flow ($13.1M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality greyWatch
- Insiders — 0 buys; 11 sells in 365 daysNote
- Capital — share repurchases were $55.0MNote
Business
Esperion Therapeutics, Inc.: Our use or display of third parties' trademarks, service marks, trade names or products in this Annual Report on Form 10-K is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us.
Where the revenue comes from
Fiscal 2025, as Esperion Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Collaboration Revenue$243.6M
- Product$159.6M
- Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received$148.8M
Leadership changes
From Esperion Therapeutics, Inc.'s own filings, the day they're filed.
- John B. Harlow Jr · appointmenteff. 2025-11-17
- Eric Warren · Chief Commercial Officer · departureeff. 2025-04-18
- JoAnne Foody · Chief Medical Officer · departureeff. 2024-08-05
Latest filings
- 8-K · Company announcement2026-07-13
- 8-K · Company announcement2026-07-08
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-09
- 8-K · Company announcement2026-06-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Esperion Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.